No abstract available
Keywords:
NPM1 mutations; blast phase CML; dasatinib.
MeSH terms
-
Algorithms
-
Antineoplastic Agents / therapeutic use
-
Basophils / pathology
-
Blast Crisis / genetics*
-
Dasatinib / therapeutic use
-
Diagnosis, Differential
-
Fusion Proteins, bcr-abl / genetics
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myeloid, Acute / genetics
-
Male
-
Middle Aged
-
Mutation, Missense*
-
Neoplasm Proteins / genetics*
-
Nucleophosmin / genetics*
-
Philadelphia Chromosome
-
Protein Kinase Inhibitors / therapeutic use
-
Sarcoma, Myeloid / etiology
Substances
-
Antineoplastic Agents
-
NPM1 protein, human
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Nucleophosmin
-
Fusion Proteins, bcr-abl
-
Dasatinib